Global Herceptin Biosimilar Market to Surpass US$ 5.8 Billion by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global herceptin biosimilar market is estimated to be valued at US$ 1.3 billion in 2020 and is expected to exhibit a CAGR of 24.5 % over the forecast period (2020-2027).

Key Trends and Analysis of the Global Herceptin Biosimilar Market:

Key players are focused on obtaining product approvals to strengthen their position in the global herceptin biosimilar market. For instance, in June 2020, Roche Holding AG received the US Food Drug and Administration approval for Phesgo, a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, a subcutaneous injection with combination with intravenous chemotherapy for treatment of early and metastatic breast cancer.

Moreover, key players are focused on launching products to strengthen their product portfolio in the global herceptin biosimilar market. For instance, in 2019, Samsungbioepis Co,.Ltd, received approval for its first oncology treatment, Ontruzant, a biosimilar of herceptin and received the approval from US Food Drug and Administration. The product is approved for treatment of metastatic HER2-overexpressing BC, early HER2-overexpressing BC, and advanced gastric cancer in the U.S.

Among regions, North America is expected to register highest growth rate due to the increasing prevalence of diseases such as colorectal cancer, breast cancer and lung cancer in women. The US National Library of Medicine’s report published in September 2020 stated that around breast, lung and colorectal cancer accounted for 50% of the overall cancer incidence in women in the US.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4258

Key Market Takeaways:

The global herceptin biosimilar market is expected to exhibit a CAGR of 24.5 % over the forecast period owing to the increasing prevalence of diseases such as gastric cancer and breast cancer in females and product approvals and launches in the global herceptin biosimilar market.

Competitive Landscape:

Key players operating in the global herceptin biosimilar market are Amgen Inc., AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4258

Market Segmentation:

  • Global Herceptin Biosimilar Market, By Indication:

    • Breast Cancer

    • Gastric Cancer

    • Others

  • Global Herceptin Biosimilar Market, By Distribution Channel :

    • Hospitals

    • Oncology Centers

    • Others

  • Global Herceptin Biosimilar Market, By Region:

    • North America

    • Latin America

      • By Country:

        • Brazil

        • Mexico

        • Argentina

        • Rest of Latin America

    • Europe

      • By Country:

        • Germany

        • U.K.

        • France

        • Italy

        • Spain

        • Russia

        • Rest of Europe

    • Asia Pacific

      • By Country:

        • China

        • India

        • Japan

        • Australia

        • South Korea

        • ASEAN

        • Rest of Asia Pacific

    • Middle East

      • By Country/Region:

        • GCC

        • Israel

        • Rest of Middle East

    • Africa

      • By Country/Region:

        • South Africa

        • Central Africa

        • North Africa

Related Market Intelligence Report:

Biosimilars Market, by Drug Class (Recombinant Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Insulin, Anticoagulants, Fusion Proteins, Erythropoietin, Monoclonal Antibodies, Follitropin, and Others), by Therapy Type (Oncology, Immunology, Hematology, Hormone Therapy, Metabolic Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Specialty Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Read more: https://www.coherentmarketinsights.com/market-insight/biosimilars-market-750

Bioprocess Analyzer Market, by Product (Instruments and Consumables), by Applications (Biologics and Biosimilars), by End Users (Biopharmaceutical Companies, Contract Manufacturing Organizations, Contract Research Organizations, and Others), and by Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

Read more: https://www.coherentmarketinsights.com/ongoing-insight/bioprocess-analyzer-market-3568

Oncology Biosimilars Market, By Cancer Type (Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Kidney Cancer, Stomach Cancer, Brain Cancer, and Others), By Product Type (Monoclonal Antibodies, Immunomodulators, and Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), By Geography – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Read more: https://www.coherentmarketinsights.com/ongoing-insight/oncology-biosimilars-market-1305

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005346/en/

Contacts

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: [email protected]
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter

Source Article